Saint Louis, Missouri-based Emerson Electric Co. (EMR) is a technology and software company that provides various solutions. With a market cap of $89.8 billion, the company offers control systems, sensors, and valves, as well as electrical infrastructure and tools for industrial, commercial, and consumer markets worldwide. The automation giant is expected to announce its fiscal fourth-quarter earnings for 2026 before the market opens on Wednesday, Nov. 4.
Ahead of the event, analysts expect Emerson Electric to report a profit of $1.85 per share on a diluted basis, up 14.2% from $1.62 per share in the year-ago quarter. The company has surpassed or met Wall Street’s EPS estimates in its last four quarterly reports.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For the full year, analysts expect Emerson Electric to report EPS of $6.56, up 9.3% from $6 in fiscal 2025. Its EPS is expected to rise 10.5% year over year to $7.25 in fiscal 2027.
www.barchart.comEMR stock has outperformed the S&P 500 Index’s ($SPX) 14.4% gains over the past 52 weeks, with shares up 19.5% during this period. Similarly, it outperformed the State Street Industrial Select Sector SPDR ETF’s (XLI) 6.8% rise over the same time frame.
www.barchart.comEmerson Electric’s outperformance is rooted in its successful transformation into a pure-play global automation leader, capitalizing on surging industrial demand for intelligent manufacturing, process control, and AI-scale data center infrastructure. Bolstered by strong operational execution, consistent sales beats, and strategic technology acquisitions, the company has consistently outpaced broader market indices as heightened factory automation activity and favorable secular trends translate into robust earnings expansion and rising analyst price targets.
Analysts’ consensus opinion on EMR stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 26 analysts covering the stock, 16 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” eight give a “Hold,” and one recommends a “Moderate Sell.” EMR’s average analyst price target is $175.96, indicating a potential upside of 11.1% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
How Nvidia Stock Can Make or Break the Anthropic IPO – and the Claude Maker’s Potential $2 Trillion Valuation A $4 Billion Reason to Take Another Look at Supermicro Stock With an IPO Brewing, Anthropic Just Launched Its Answer to Meta’s Uber-Popular Muse Ahead of Verizon Earnings, Here's What Barchart Data Says Comes Next for VZ Stock